Tenon Medical, Inc. (TNON)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
No matching records found (checked Nov 16, 2026)
ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 100/100 (CRITICAL), 2.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Evidence and freshness
Record counts and statuses were computed on 2026-11-17. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 0 | No records No matching records found (checked Nov 16, 2026) |
ClinicalTrials.gov checked Nov 16, 2026 |
| Insider activity | 0 | Unavailable No record on file; source last refreshed Nov 17, 2026 |
SEC EDGAR Form 4 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 17, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 17, 2026 |
| Publications | 6 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 16, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 23.1/100 (grade F):
- Dilution risk: signal score 1.00, weight used 22%, 21.9 points
- Short interest: signal score 0.10, weight used 8%, 0.8 points
- Publications: signal score 0.30, weight used 1%, 0.4 points
- Clinical trials: signal score 0.00, weight used 68%, 0.0 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- Tenon Medical (TNON) Q3 2026 Earnings Call Transcript
- Tenon Medical, Inc. Q3 2026 Earnings Call Summary
- Tenon Medical Inc (TNON) (Q3 2026) Earnings Call Highlights: Revenue Climbs 22% as Debt Is ...
- Tenon(R) Medical Reports Third Quarter 2026 Financial Results
- Tenon Medical, Inc. Sets Date for Third Quarter 2026 Earnings
- Tenon Medical(R) Adds Eight New Patents Issued by the United States Patent and Trademark Office Through Q3 2026
- Tenon(R) Medical Announces Full Commercial Launch of the SImmetry(R)+ SI Joint Fusion 3D Printed Lateral Screw Following Successful Alpha Launch
- WallachBeth Capital Announces Closing of Tenon Medical Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Prevention of post-natal acquisition of neonatal herpes: evaluation of an educational tool for pregnant women compared to routine prenatal care. — Eur J Pediatr 2026 Sep 16 PMID 42749933
- Twelve-month clinical and radiographic outcomes following inferior-posterior sacroiliac joint fusion using the Catamaran SI Joint Fusion System: a prospective, multi-center evaluation. — Expert Rev Med Devices 2025 Oct PMID 40773478
- Catamaran SI Joint Fusion System((R)) MAINSAIL(TM) Study: a prospective, single-arm, multi-center, post-market study of six-month clinical outcomes and twelve-month radiographic findings. — Expert Rev Med Devices 2024 Sep PMID 39161110
- Neonatal herpes: case series in two obstetric centres over a 10-year period (2013-2023), France. — Eur J Pediatr 2024 Aug PMID 38678161
- Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. — ESMO Open 2020 Oct PMID 33097652
6 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Tenon Medical, Inc..
Full TNON Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.